Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05426889
Other study ID # 2022-0219
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 2, 2022
Est. completion date December 20, 2023

Study information

Verified date May 2022
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact sheng Chen, M.D.
Email saintchan@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic subdural hematoma (CSDH) is a very common hemorrhagic disease of the nervous system, accounting for about 10% of hemorrhagic strokes. The incidence rate of elderly people over 65 years old is 58.1/100,000, and the incidence rate is increasing year by year, and it may reach 121/100,000 by 2030. At present, the specific pathogenesis of CSDH is still unclear. Although it has been clinically confirmed that a part of CSDH can be absorbed by itself, and some drugs such as atorvastatin can speed up the process, surgical treatments such as cranial craniotomy or cranial drilling hematoma removal are still the only options for patients with CSDH. Lymphatic circulation spreads throughout most tissues of the human body, assists in removing metabolic wastes in the interstitium, maintains body fluid homeostasis, and plays a role in immune response and immune surveillance. For a long time, the central nervous system has been considered as an immune-privileged organ, that is, the central nervous system does not have the presence of the lymphatic system. Until 2015, Louveau et al. used immunofluorescence staining and other techniques to find functional lymphatic ducts adjacent to the dural venous sinuses in the mouse brain when looking for the channels for T cells to enter and leave the meninges, confirming the first intracranial meningeal lymphatic vessels. (mLVs), and found that mLVs express the classic markers of lymphatic endothelial cells (LECs), namely VEGFR3, prostate homeobox 1 (PROX 1), podoplanin, lymphatic endothelial markers transparent Ronidase receptor-1 (LYVE-1), etc. Relevant studies have confirmed that meningeal lymphatic vessels can drain interstitial fluid (ISF), macromolecular substances and immune cells out of the skull, providing a new drainage pathway for the excretion of metabolic waste from the central nervous system. Subsequent studies have confirmed that mLV is involved in the pathophysiological process of a series of neurological diseases such as Alzheimer's disease (AD), traumatic brain injury (TBI), and subarachnoid hemorrhage (SAH). This phenomenon suggests that mLVs play an important role in central nervous system diseases.


Description:

Chronic subdural hematoma (CSDH) is a very common hemorrhagic disease of the nervous system, accounting for about 10% of hemorrhagic strokes. The incidence rate of elderly people over 65 years old is 58.1/100,000, and the incidence rate is increasing year by year, and it may reach 121/100,000 by 2030. At present, the specific pathogenesis of CSDH is still unclear. Although it has been clinically confirmed that a part of CSDH can be absorbed by itself, and some drugs such as atorvastatin can speed up the process, surgical treatments such as cranial craniotomy or cranial drilling hematoma removal are still the only options for patients with CSDH. However, these surgical methods have a high recurrence rate of hematoma and the incidence of surgery-related complications, which brings a huge burden to the patient's family and society. Despite the presence of a large number of inflammatory cytokines in the CSDH content, only a minority of patients exhibited systemic inflammatory responses such as fever and increased white blood cell count during hematoma resorption. On the contrary, more CSDH patients showed a certain degree of neurological deficit symptoms, such as hemiplegia of one limb and cognitive function decline. These clinical phenomena have stimulated thinking about how CSDH is drained. If the hematoma is absorbed through the vascular system, why is no corresponding inflammatory response or clinical symptoms observed in CSDH patients. In addition, the cerebrospinal fluid (CSF) of patients with CSDH was clear and the cell count was within the normal range, indicating that CSDH did not flow into the CSF. Therefore, further exploring the drainage pathway of CSDH, understanding the absorption process and recurrence mechanism of CSDH, and developing new effective treatment methods are important issues faced by neurosurgery clinicians. Lymphatic circulation spreads throughout most tissues of the human body, assists in removing metabolic wastes in the interstitium, maintains body fluid homeostasis, and plays a role in immune response and immune surveillance. For a long time, the central nervous system has been considered as an immune-privileged organ, that is, the central nervous system does not have the presence of the lymphatic system. Until 2015, Louveau et al. used immunofluorescence staining and other techniques to find functional lymphatic ducts adjacent to the dural venous sinuses in the mouse brain when looking for the channels for T cells to enter and leave the meninges, confirming the first intracranial meningeal lymphatic vessels. (mLVs), and found that mLVs express the classic markers of lymphatic endothelial cells (LECs), namely VEGFR3, prostate homeobox 1 (PROX 1), podoplanin, lymphatic endothelial markers transparent Ronidase receptor-1 (LYVE-1), etc. Relevant studies have confirmed that meningeal lymphatic vessels can drain interstitial fluid (ISF), macromolecular substances and immune cells out of the skull, providing a new drainage pathway for the excretion of metabolic waste from the central nervous system. Subsequent studies have confirmed that mLV is involved in the pathophysiological process of a series of neurological diseases such as Alzheimer's disease (AD), traumatic brain injury (TBI), and subarachnoid hemorrhage (SAH). This phenomenon suggests that mLVs play an important role in central nervous system diseases.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 20, 2023
Est. primary completion date December 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Clinical diagnosis chronic subdural hematoma - Hematoma thickness greater than 10mm on imaging Exclusion Criteria: - In patients with chronic subdural hematoma, only head CT examination was performed; - There was previous brain injury (stroke, cerebral hemorrhage, etc., leaving relevant chronic changes on CT); - Imaging data was lost and the onset of CSDH was accompanied by severe comorbidity disease patients.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
subdural hematoma burr hole drainage
For patients with larger hematoma, remove the hematoma by burr hole drainage
Drug:
drug conservative treatment
The patient did not receive surgical treatment and chose conservative treatment

Locations

Country Name City State
China Second affiliated hosipital of zhejiang univerisity school of medicine Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Magnetic resonance signal intensity of meningeal lymphatic vessels The signal intensity of meningeal lymphatic vessels was measured by PACS system in hospital The first day after admission
Primary Magnetic resonance signal intensity of meningeal lymphatic vessels The signal intensity of meningeal lymphatic vessels was measured by PACS system in hospital 3 days after surgery
Primary Magnetic resonance signal intensity of meningeal lymphatic vessels The signal intensity of meningeal lymphatic vessels was measured by PACS system in hospital 1 months after surgery
Primary Magnetic resonance signal intensity of meningeal lymphatic vessels The signal intensity of meningeal lymphatic vessels was measured by PACS system in hospital 6 months after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04742920 - The Onyx™ Trial For The Embolization Of The Middle Meningeal Artery For Chronic Subdural Hematoma (OTEMACS) N/A
Recruiting NCT05327933 - Preventing Recurrences of Chronic Subdural Hematoma in Adult Patients by Middle Meningeal Artery Embolization N/A
Completed NCT01930617 - Irrigation of Chronic Subdural Hematomas - is More Better? N/A
Recruiting NCT03582293 - Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma Phase 3
Terminated NCT00915928 - Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors N/A
Completed NCT03755349 - Covers to Improve Esthetic Outcome After Surgery for Chronic Subdural Hematoma N/A
Terminated NCT02362321 - Role of Dexamethasone in the Conservative Treatment of Chronic Subdural Hematoma Phase 4
Recruiting NCT04573387 - Exhaustive Drainage Versus Fixed-time Drainage for Chronic Subdural Hematoma After One-burr Hole Craniostomy N/A
Withdrawn NCT03845322 - Curcumin/Turmeric as a Treatment for Patients With Subdural Hematomas Recurrence Early Phase 1